2023
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency
Stecklein S, Barlow W, Pusztai L, Timms K, Kennedy R, Logan G, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. JCO Precision Oncology 2023, 7: e2300197. PMID: 37972336, PMCID: PMC10681491, DOI: 10.1200/po.23.00197.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHomologous recombination deficiencyBreast cancerAdjuvant anthracycline-based chemotherapyTherapeutic vulnerabilitiesRecombination deficiencyDistinct therapeutic vulnerabilitiesAnthracycline-based chemotherapyImmune response signaturesDNA-damaging therapiesFavorable prognosisIntermediate prognosisWorse prognosisImmunologic microenvironmentImmune responseChemoresistant tumorsPrognostic classificationHeterogeneous diseasePrognosisHeterogeneous groupDistinct subgroupsTumorsCancerResponse signatureSimultaneous assessment
2013
Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer
Matsuo T, Nishizuka SS, Ishida K, Endo F, Katagiri H, Kume K, Ikeda M, Koeda K, Wakabayashi G. Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer. World Journal Of Surgical Oncology 2013, 11: 11. PMID: 23339659, PMCID: PMC3562164, DOI: 10.1186/1477-7819-11-11.Peer-Reviewed Original ResearchConceptsDose-response curveChemosensitivity testGastric cancerResistant cancer cell populationsStandard chemotherapy regimensPeak plasma concentrationDose-response patternDrug dose-response curvesPrimary chemotherapyChemotherapy regimensRecurrent diseaseStandard chemotherapyResultsA totalChemosensitivity evaluationPlasma concentrationsChemosensitivity patternsChemoresistant tumorsResistant patternChemotherapyDrug resistanceDrug sensitivityCancer cell populationsConclusionsThese resultsCisplatinCell populations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply